# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Evel Knievel (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-RB001-SYN-TD
- Date: 1996-01-12
- Fictional facility: St. Posthumous Health Center
- Fictional author: Dale Rasmussen, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- Pain in the back, hips and knees every day from old fractures, worse in the morning and after travel; ibuprofen three times a day for years **S**
- Tired for months; noticed small red spots on his chest and wonders whether the old transfusions or his drinking have hurt his liver **S**
- He wants to keep walking and playing golf and does not want to depend on strong pain pills **S**
- Two falls in the past year; he worries about breaking another bone **S**

## Your goals

- Hepatitis C confirmed or excluded and liver disease staged within three weeks. Target: 1996-01-26. Recorded outcome: Chronic hepatitis C, genotype 1a, with compensated cirrhosis staged at two weeks. **S**
- Cure of hepatitis C: HCV RNA not detected 12 or more weeks after treatment. Target: 1996-08-17. Recorded outcome: HCV RNA not detected 13 weeks after a 12-week course. **S**
- No decompensation (ascites, variceal bleeding, encephalopathy or jaundice); Child-Pugh A and MELD-Na below 15. Target: 1996-08-17. Recorded outcome: No decompensation; Child-Pugh A5; MELD-Na 6 after cure. **S**
- No alcohol. Target: 1996-08-17. Recorded outcome: No alcohol since the start of antiviral treatment; AUDIT-C 0. **S**
- Pain 4 of 10 or less, walking 30 minutes, with no oral NSAIDs or opioids. Target: 1996-08-17. Recorded outcome: Pain 4 of 10; walking 30 minutes in the pool and on flat ground; no NSAIDs or opioids. **S**
- Glucose management indicator below 7% without hypoglycemia. Target: 1996-08-17. Recorded outcome: Glucose management indicator 6.8%; no hypoglycemia. **S**
- Vitamin D replete and osteoporosis treatment started; no falls with injury. Target: 1996-08-17. Recorded outcome: Vitamin D 34 ng/mL; zoledronic acid given; no further falls. **S**

## What we agreed to do

- Hepatology consultation within three weeks to confirm and stage chronic liver disease and plan antiviral treatment if hepatitis C is confirmed. Guideline: AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Simplified HCV treatment algorithm for treatment-naive adults with compensated cirrhosis (2023); Singal AG, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023;78(6):1922-1965 (PMID 37199193) (2023) **S**
- Liver work-up for raised transaminases and low platelets: hepatitis C antibody with reflex RNA, hepatitis B surface antigen, core antibody and surface antibody, hepatitis A IgG, HIV, INR, ultrasound of the abdomen, and FIB-4 from today's tests. Guideline: AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Simplified HCV treatment algorithm for treatment-naive adults with compensated cirrhosis (2023); Hepatitis C Virus Infection in Adolescents and Adults: Screening (2020) **S**
- Pain care safe in liver disease: stop ibuprofen and omeprazole; acetaminophen up to 2 g a day; topical diclofenac for the knees; no opioids; physical and aquatic therapy; heat, pacing and sleep routines; pain coping skills. Guideline: Rakoski M, Goyal P, Spencer-Safier M, et al. Pain management in patients with cirrhosis. Clin Liver Dis (Hoboken) 2018;11(6):135-140 (PMID 30992804) (2018); Dowell D, et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep 2022;71(3):1-95 (PMID 36327391) (2022) **S**
- Alcohol: brief counseling toward stopping completely, because alcohol speeds liver scarring; follow-up AUDIT-C at each visit; counseling or medicine for alcohol use offered if he cannot stop. Guideline: Crabb DW, et al. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the AASLD. Hepatology 2020;71(1):306-333 (PMID 31314133) (2019); Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018) **S**
- Sofosbuvir-velpatasvir one tablet daily for 12 weeks under the AASLD-IDSA simplified pathway for compensated cirrhosis, after hepatitis B testing and a drug interaction check (no proton pump inhibitor; watch for muscle pain on atorvastatin); glucose monitoring for hypoglycemia; HCV RNA and liver tests 12 or more weeks after the last dose. Guideline: AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Simplified HCV treatment algorithm for treatment-naive adults with compensated cirrhosis (2023); AASLD-IDSA HCV Guidance: Monitoring patients who are starting HCV treatment, are on treatment, or have completed therapy (2026); EPCLUSA (sofosbuvir and velpatasvir) tablets, prescribing information (2025) **S**
- Carvedilol for clinically significant portal hypertension (liver stiffness 25 kPa or more), started at 6.25 mg and raised to 12.5 mg daily if blood pressure allows; no screening endoscopy while he takes it; liver stiffness and platelets rechecked a year after cure. Guideline: de Franchis R, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol 2022;76(4):959-974 (PMID 35120736) (2022); Kaplan DE, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology 2024;79(5):1180-1211 (PMID 37870298) (2024) **S**
- Liver cancer surveillance by ultrasound with alpha-fetoprotein every six months, continuing after cure because cirrhosis remains. Guideline: AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Simplified HCV treatment algorithm for treatment-naive adults with compensated cirrhosis (2023); Singal AG, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023;78(6):1922-1965 (PMID 37199193) (2023) **S**
- Vaccines for chronic liver disease: hepatitis A (two doses) and hepatitis B (two doses), then influenza, pneumococcal and zoster vaccines at the preventive visit. Guideline: AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Simplified HCV treatment algorithm for treatment-naive adults with compensated cirrhosis (2023); Adult Immunization Schedule by Medical Condition and Other Indication (2026) **S**
- Teaching on decompensation (swelling of the abdomen or legs, black stools or vomiting blood, confusion, yellow eyes) with same-day contact; transplant referral only if decompensation occurs or the MELD-Na reaches 15. Guideline: Kaplan DE, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology 2024;79(5):1180-1211 (PMID 37870298) (2024); Biggins SW, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the AASLD. Hepatology 2021;74(2):1014-1048 (PMID 33942342) (2021) **S**
- Diabetes care adapted to cirrhosis: metformin continued while kidney function is normal and he does not drink; continuous glucose monitoring because the A1c can read falsely low; moderate-intensity statin; yearly eye and foot examinations and urine albumin. Guideline: American Diabetes Association. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S61-S88 (PMID 41358897) (2026); American Diabetes Association. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S132-S149 (PMID 41358894) (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, osteoporosis and depression monographs (2026) **S**
- Falls and fractures: physical therapy and a home safety review; vitamin D; bone density scan, since cirrhosis, alcohol and many old fractures raise the risk of osteoporosis. Guideline: Watts NB, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97(6):1802-1822 (PMID 22675062) (2012); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, osteoporosis and depression monographs (2026) **S**
- Zoledronic acid 5 mg intravenously once a year, after vitamin D repletion and a normal calcium, rather than an oral bisphosphonate because of portal hypertension; dental review first; bone density again in two years. Guideline: Watts NB, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97(6):1802-1822 (PMID 22675062) (2012); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, osteoporosis and depression monographs (2026) **S**
- Depression and distress screening at each visit, and plain explanations with written information. Guideline: CMID: Clinical Monitoring Intelligence Database, diabetes type 2, osteoporosis and depression monographs (2026); Depression and Suicide Risk in Adults: Screening (2023) **S**

## Follow-up

- 1996-01-12: New patient: chronic pain from old fractures, diabetes, and raised liver tests with low platelets on today's tests: hepatitis C and liver work-up, NSAIDs stopped, alcohol counseling, and hepatology review booked **S**
- 1996-01-26: Hepatitis C confirmed with compensated cirrhosis: elastography, hepatology consultation, carvedilol for portal hypertension, statin, vaccines, and the antiviral plan **S**
- 1996-02-23: Day 1 of sofosbuvir-velpatasvir: drug interaction check, carvedilol titration, glucose monitoring, vitamin D, and the bone density plan **S**
- 1996-05-18: End of 12 weeks of antiviral treatment: liver tests, glucose monitoring in cirrhosis, osteoporosis, pain, and abstinence **S**
- 1996-08-17: Cure confirmed (SVR12): six-month liver cancer surveillance, cirrhosis care after cure, and transplant criteria reviewed **S**
- 1996-09-21: Periodic adult preventive visit **S**

This teaching document does not replace care from a qualified clinician.
